Objective: The efficacy of the proton pump inhibitor pantoprazole in the tr
eatment of several acid-related diseases has been demonstrated in a number
of clinical trials. The objective of this observational study was to observ
e the tolerability and efficacy of intravenous pantoprazole in routine clin
Design and Setting: Observational multicentre study conducted in inpatients
of 17 German university and community-based hospitals.
Study Participants: 269 patients over the age of 18 years with gastric or d
uodenal ulcer, reflux oesophagitis or other gastroduodenal disease were inc
luded in the study. 214 patients (80%) suffered from a concomitant disease.
Intervention: Patients were treated with intravenous pantoprazole.
Main Outcome Measures and Results: Efficacy of the drug was good. In 241 pa
tients (92%), treatment led to an improvement of the disease. The confidenc
e interval of the relative frequency of treatment success was 91.9 to 92.1%
. The multimorbidity rate of the study population was high and most patient
s received concomitant medication. Nevertheless, tolerability of the drug w
as assessed to be 'very good' or 'good' in 263 patients. Two 'unwanted drug
reactions' occurred, but their relation to the intake of the study medicat
ion was judged to be 'unlikely'.
Conclusion: Intravenous pantoprazole is a well tolerated and effective drug
for the routine clinical treatment of acid-related diseases in patients wi
th a number of concomitant diseases.